US 12,414,948 B2
Methods
Sophie Dutheil, Stamford, CT (US); Gretchen Snyder, New York, NY (US); Peng Li, New Milford, NJ (US); and Robert E. Davis, San Diego, CA (US)
Assigned to INTRA-CELLULAR THERAPIES, INC., Bedminster, NJ (US)
Filed by INTRA-CELLULAR THERAPIES, INC., New York, NY (US)
Filed on Nov. 22, 2023, as Appl. No. 18/518,436.
Application 18/518,436 is a continuation in part of application No. 18/320,173, filed on May 18, 2023.
Claims priority of provisional application 63/343,192, filed on May 18, 2022.
Prior Publication US 2024/0122924 A1, Apr. 18, 2024
Int. Cl. A61K 31/4985 (2006.01); A61P 25/18 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 29/00 (2006.01)
CPC A61K 31/4985 (2013.01) [A61P 25/18 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); A61P 29/00 (2018.01)] 27 Claims
 
1. A method for the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis comprising administering to a patient in need thereof a Compound of Formula I:

OG Complex Work Unit Chemistry
wherein:
X is —N(CH3)—; and
Y is —C(═O)—;
in free base, or pharmaceutically acceptable salt form;
wherein the patient has elevated levels of one or more biomarkers indicative of peripheral inflammation in the blood, plasma, serum, peripheral blood mononuclear cells (PBMC), or urine; and
wherein the psychiatric disorder and/or the psychiatric symptom is depression, anxiety, psychosis, anhedonia, memory loss, impairment of executive functioning, difficulty concentrating, seizures, difficulty sleeping, hallucination, change in personality, or any combination thereof.